Seeking Alpha

More on Jazz Pharma (JAZZ): Q4 EPS easily beats estimates. Net sales of Xyrem were $113.5M,...

More on Jazz Pharma (JAZZ): Q4 EPS easily beats estimates. Net sales of Xyrem were $113.5M, compared to net sales of $71.8M for Q411. Gross margin was 85.8% compared to 95.2% for 2011. For FY13, the company expects an EPS of $5.70-5.90 on sales of $805M - 835M, above Street estimates of $5.67 on revenue of $811.3M. Shares +2% AH.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector